{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:48:23Z","timestamp":1762004903356},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.diagmicrobio.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T14:01:25Z","timestamp":1492956085000},"page":"271-275","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model"],"prefix":"10.1016","volume":"88","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Denisuik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Pitout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Noreddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2017.04.007_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01643430","article-title":"Degree of absorption pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity","volume":"18","author":"Bergan","year":"1990","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0010","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Sixth Informational Supplement. M100-S26","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0015","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically \u2013 Tenth Edition: Approved Standard M07-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.04.007_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/dkt027","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamase-, AmpC \u03b2-lactamase-, and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 Year Period: CANWARD 2007-2011","volume":"68","author":"Denisuik","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0025","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance","volume":"59","author":"Docobo-Perez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multi-drug resistant including extended-spectrum \u03b2-lactamase producing Enterobacteriaceae infections: a systemic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"10.1016\/j.diagmicrobio.2017.04.007_bb0035","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2014.12842","article-title":"Diagnosis and management of urinary tract infections in the outpatient setting","volume":"312","author":"Grigoryan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0045","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.02399-13","article-title":"In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study","volume":"58","author":"Karlowsky","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0050","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: A review of its use as a single dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2006.05.019","article-title":"Pharmacokinetic and pharmacodynamics aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections","volume":"28","author":"Mazzei","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine: a review of its antibacterial activity pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.04.007_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000222042","article-title":"Fosfomycin: absorption and excretion","volume":"23","author":"Shimizu","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0070","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0075","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1128\/AAC.04955-14","article-title":"Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model","volume":"59","author":"VanScoy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0080","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00355-16","article-title":"Relationship between fosfomycin exposure and amplification of Escherichia coli subpopulations with reduced susceptibility in a hollow-fiber infection model","volume":"60","author":"VanScoy","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.04.007_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkt022","article-title":"Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals: Results of the CANWARD 2007-2011 study","volume":"68","author":"Zhanel","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0090","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1093\/jac\/dku149","article-title":"Pharmacodynamic activity of ertapenem versus genotypically characterized extended spectrum \u03b2-lactamase (ESBL) or KPC or NDM producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in-vitro model","volume":"69","author":"Zhanel","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.04.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2082693","article-title":"Fosfomycin A first-line oral therapy for acute uncomplicated cystitis","author":"Zhanel","year":"2016","journal-title":"Can J Infect Dis Med Microbiol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317301359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317301359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T17:16:48Z","timestamp":1569086208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317301359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0732889317301359"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.04.007","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}